Latest news with #LanternPharma
Yahoo
5 days ago
- Business
- Yahoo
Here's Why We're Watching Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But while history lauds those rare successes, those that fail are often forgotten; who remembers So should Lantern Pharma (NASDAQ:LTRN) shareholders be worried about its cash burn? In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. Let's start with an examination of the business' cash, relative to its cash burn. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. When Lantern Pharma last reported its March 2025 balance sheet in May 2025, it had zero debt and cash worth US$20m. Importantly, its cash burn was US$19m over the trailing twelve months. Therefore, from March 2025 it had roughly 12 months of cash runway. While that cash runway isn't too concerning, sensible holders would be peering into the distance, and considering what happens if the company runs out of cash. Depicted below, you can see how its cash holdings have changed over time. View our latest analysis for Lantern Pharma Lantern Pharma didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. Over the last year its cash burn actually increased by 40%, which suggests that management are increasing investment in future growth, but not too quickly. However, the company's true cash runway will therefore be shorter than suggested above, if spending continues to increase. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company. While Lantern Pharma does have a solid cash runway, its cash burn trajectory may have some shareholders thinking ahead to when the company may need to raise more cash. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Commonly, a business will sell new shares in itself to raise cash and drive growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn. Lantern Pharma's cash burn of US$19m is about 57% of its US$34m market capitalisation. That's high expenditure relative to the value of the entire company, so if it does have to issue shares to fund more growth, that could end up really hurting shareholders returns (through significant dilution). On this analysis of Lantern Pharma's cash burn, we think its cash runway was reassuring, while its cash burn relative to its market cap has us a bit worried. After looking at that range of measures, we think shareholders should be extremely attentive to how the company is using its cash, as the cash burn makes us uncomfortable. On another note, we conducted an in-depth investigation of the company, and identified 6 warning signs for Lantern Pharma (3 make us uncomfortable!) that you should be aware of before investing here. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies with significant insider holdings, and this list of stocks growth stocks (according to analyst forecasts) Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Business
- Yahoo
Here's Why We're Watching Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But while history lauds those rare successes, those that fail are often forgotten; who remembers So should Lantern Pharma (NASDAQ:LTRN) shareholders be worried about its cash burn? In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. Let's start with an examination of the business' cash, relative to its cash burn. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. When Lantern Pharma last reported its March 2025 balance sheet in May 2025, it had zero debt and cash worth US$20m. Importantly, its cash burn was US$19m over the trailing twelve months. Therefore, from March 2025 it had roughly 12 months of cash runway. While that cash runway isn't too concerning, sensible holders would be peering into the distance, and considering what happens if the company runs out of cash. Depicted below, you can see how its cash holdings have changed over time. View our latest analysis for Lantern Pharma Lantern Pharma didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. Over the last year its cash burn actually increased by 40%, which suggests that management are increasing investment in future growth, but not too quickly. However, the company's true cash runway will therefore be shorter than suggested above, if spending continues to increase. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company. While Lantern Pharma does have a solid cash runway, its cash burn trajectory may have some shareholders thinking ahead to when the company may need to raise more cash. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Commonly, a business will sell new shares in itself to raise cash and drive growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn. Lantern Pharma's cash burn of US$19m is about 57% of its US$34m market capitalisation. That's high expenditure relative to the value of the entire company, so if it does have to issue shares to fund more growth, that could end up really hurting shareholders returns (through significant dilution). On this analysis of Lantern Pharma's cash burn, we think its cash runway was reassuring, while its cash burn relative to its market cap has us a bit worried. After looking at that range of measures, we think shareholders should be extremely attentive to how the company is using its cash, as the cash burn makes us uncomfortable. On another note, we conducted an in-depth investigation of the company, and identified 6 warning signs for Lantern Pharma (3 make us uncomfortable!) that you should be aware of before investing here. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies with significant insider holdings, and this list of stocks growth stocks (according to analyst forecasts) Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-05-2025
- Business
- Yahoo
EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients
The U.S. Food and Drug Administration (FDA) on Monday cleared the amendment to Lantern Pharma Inc.'s (NASDAQ:LTRN) Investigational New Drug (IND) application for the Phase 1b/2 trial of LP-184 in a genomically defined patient population of non-small cell lung cancer (NSCLC). The biomarker-focused Phase 1b/2 trial is designed to target high-risk NSCLC subtypes by evaluating LP-184 in combination with Bristol-Myers Squibb & Co.'s (NYSE:BMY) immune checkpoint inhibitors, Opdivo (nivolumab) and Yervoy (ipilimumab) in patients with advanced NSCLC harboring KEAP1 and/or STK11 mutations and low PD-L1 study is designed to assess safety, preliminary efficacy, and biomarker correlations, potentially paving a path toward accelerated development. Lantern Pharma expects to prepare an application for a Fast Track or Accelerated Approval Designation for this patient population based on data from the planned trial and ongoing analysis from existing models. The company said the median overall survival for newly diagnosed, advanced NSCLC with KEAP1 and/or STK11 mutations treated with checkpoint inhibitors and chemotherapy is estimated to be 15 months, and this population presents an annual market opportunity of over $2 billion. In December 2024, the FDA granted Fast Track Designation for LP-184 for Triple-Negative Breast Cancer (TNBC). This marked the second Fast Track Designation received for LP-184 in 2024, following its designation for Glioblastoma in October. LP-184 has demonstrated significant preclinical efficacy in TNBC models, including those resistant to PARP inhibitors, and recent data shows promising synergy with checkpoint inhibitors in TNBC. In November 2024, Lantern Pharma and its wholly-owned subsidiary Starlight Therapeutics announced the presentation of new preclinical data and Phase 1b trial design for LP-184 in glioblastoma. Following the determination of the Maximum Tolerated Dose and/or Recommended Phase 2 Dose from the ongoing Phase 1a study, Starlight Therapeutics plans to initiate a Phase 1b trial evaluating LP-184/STAR-001 in two cohorts of recurrent GBM patients: one arm anticipates administration of STAR-001 as monotherapy and the other arm anticipates administration of STAR-001 in combination with spironolactone (200 mg daily). The trial will assess safety, pharmacokinetics, and objective response using RANO 2.0 criteria. Additionally, the study will evaluate biomarkers, including PTGR1 expression, ERCC3 levels, and DNA damage markers, to help identify patients most likely to respond to treatment. Price Action: LTRN stock traded lower by 3.02% to $3.86 premarket at the last check on Monday. Read Next:UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11-05-2025
- Business
- Yahoo
LTRN: IND Clearance for LP-184 in TNBC
By John Vandermosten, CFA NASDAQ:LTRN A May 5th press release indicated that the FDA cleared Lantern Pharma, Inc.'s (NASDAQ:LTRN) LP-184 trial in triple negative breast cancer (TNBC). Lantern will now run a Phase Ib/II clinical trial evaluating LP-184 both as a monotherapy and in combination with olaparib. The trial will evaluate Lantern's candidate in recurrent, advanced-stage TNBC patients with the BRCA1 or BRCA2 mutation. Endpoints will include safety and efficacy with the goal to support design and execution of registrational studies. Clinical Trial Design The Phase Ib/II trial for LP-184 will enroll approximately 30 patients in the monotherapy arm with advanced stage TNBC. This arm will focus on identifying the optimal dose to maximize safety and potential efficacy for TNBC patients. The combination trial will evaluate LP-184 with olaparib in second-line settings for patients with advanced stage TNBC with BRCA1 or BRCA mutations. The primary endpoints for the study include safety and efficacy sufficient to support regulatory studies. The trial will be run at several centers in the United States and academic centers and institutions in India and Nigeria. The sites overseas have access to populations with a higher incidence of TNBC and leverage collaborative research networks in these countries. LP-184 LP-184 is a novel, clinical-stage small molecule drug which belongs to the acylfulvene class of molecules and functions as a prodrug. The candidate is designed to be preferentially activated in cancer cells that overexpress a specific enzyme, Prostaglandin Reductase 1 (PTGR1). Once activated by PTGR1, LP-184 becomes a potent alkylating agent. It works by binding to the DNA of cancer cells, creating DNA adducts which triggers cell apoptosis. Lantern is developing LP-184 in several cancer indications including pancreatic, glioblastoma, atypical teratoid rhabdoid tumors, ovarian, bladder, prostate, lung and TNBC. LP-184 has received multiple expedited designations from the FDA including Orphan Drug, Fast Track and Rare Pediatric Disease. Olaparib Olaparib (branded Lynparza) is a poly ADP-ribose polymerase (PARP)[1] inhibitor that is used to bring about synthetic lethality in mutated breast cancer cells. Olaparib is a targeted therapy used in patients whose cancer is associated with an inherited mutation in the breast cancer (BRCA)1 or BRCA2 genes. The drug also works with other homologous recombination deficiencies (HRD) and prevents these cells from repairing their DNA, leading to cancer cell death. First approved in 2024, olaparib is used in ovarian, prostate and pancreatic cancer. It is also approved in HER2 negative breast cancer with BRCA mutations. Treatment begins after surgery and chemotherapy for high-risk early-stage disease or for metastatic disease that has progressed after other treatments. Triple Negative Breast Cancer (TNBC) TNBC is a type of breast cancer that lacks three receptors: estrogen (ER), progesterone (PR) and human epidermal growth factor 2. The lack of these receptors means that these TNBC patients will not benefit from therapies that use these receptors to fight cancer. This includes drugs like tamoxifen and aromatase inhibitors, which target ER or PR, medications such as trastuzumab and pertuzumab, which target the HER2 protein. Many targeted therapies that have shown success in other breast cancer types have failed in TNBC clinical trials, largely due to the lack of actionable molecular targets and the heterogeneity of TNBC.[2] TNBC accounts for ~15% of the 320,000 annual breast cancer cases in the United States.[3] The incidence of TNBC has shown a steady increase over time, with over two million cases reported globally in 2018.[4] This subtype of breast cancer has the worst prognosis of breast cancers, especially if metastatic.[5] Lantern notes that nearly 70% of TNBCs harbor deficiencies in homologous recombination pathways, which make the tumors sensitive to LP-184 and suggests that olaparib will work well in combination. It also notes that average survival for newly diagnosed, metastatic TNBC is about 18 months, highlighting the severity of the unmet need. To demonstrate the efficacy of LP-184 in TNBC, Lantern included the results of preclinical work that shows how its candidate is able to shrink tumors in both PARPi resistant and PARPi sensitive tumors. Lantern conducted further LP-184 animal studies using a patient-derived xenograft (PDX) model where tumor tissue from human breast cancer is implanted into a mouse. The implanted tumor was resistant to the PARP inhibitor and produced evidence of re-sensitization in combination with LP-184 as shown in Exhibit II. Lantern's continued advancement of LP-184 in a variety of cancer types and its arsenal of expedited pathways make it an attractive asset in the company's pipeline. The indication in TNBC joins other clinical assets including other LP-184 indications, STAR-001 in CNS indications, LP-284 in recurrent non-Hodgkin's lymphoma and LP-300 in non-small cell lung cancer for never smokers. SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer . ________________________ [1] PARP is an enzyme that helps repair damaged DNA in cells. [2] Salimbeni, B.T., et al. The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022. [3] American Cancer Society. Cancer Statistics, 2025. [4] Singh S., et al. Role of Immune Checkpoint Inhibitors in the Revolutionization of Advanced Melanoma Care. International Immunopharmacology. 2020 [5] National Cancer Institute. Cancer Stat Facts: Female Breast Cancer Subtypes. Sign in to access your portfolio
Yahoo
20-03-2025
- Business
- Yahoo
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET
Webcast to be held Thursday, March 27th, 4:30 p.m. ET, register for the webcast here, or at the link provided below. DALLAS, March 20, 2025--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical stage drug programs, today announced that it will host its fourth quarter and fiscal year 2024 operating and financial results webcast on Thursday, March 27, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Management intends to discuss the operating and financial results for the fourth quarter and fiscal year ended December 31, 2024 and provide guidance on upcoming milestones, clinical trials and developments of the AI platform, RADR®. Panna Sharma, President and Chief Executive Officer of Lantern Pharma, will lead the call and will be joined by other members of the management team. To register for the webinar, please sign up at the Zoom webcast link provided in the link: Lantern Pharma Q4, 2024 earnings Zoom webcast registration link. A replay of the earnings call webcast will be available after the call on the investor relations section of the Company's website: About Lantern Pharma Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 100 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0 - 2.5 million per program. Our lead development programs include a Phase 2 clinical program and multiple Phase 1 clinical trials. We have also established a wholly-owned subsidiary, Starlight Therapeutics, to focus exclusively on the clinical execution of our promising therapies for CNS and brain cancers, many of which have no effective treatment options. Our AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD and have the potential to provide life-changing therapies to hundreds of thousands of cancer patients across the world. Additional information: Website: LinkedIn: X: @lanternpharma Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "model," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that our research and the research of our collaborators may not be successful, (ii) the risk that observations in preclinical studies and early or preliminary observations in clinical studies do not ensure that later observations, studies and development will be consistent or successful, (iii) the risk that we may not be able to secure sufficient future funding when needed and as required to advance and support our existing and planned clinical trials and operations, (iv) the risk that we may not be successful in licensing potential candidates or in completing potential partnerships and collaborations, (v) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (vi) the risk that no drug product based on our proprietary RADR® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (vii) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on March 18, 2024. You may access our Annual Report on Form 10-K for the year ended December 31, 2023 under the investor SEC filings tab of our website at or on the SEC's website at Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations. View source version on Contacts Investor Relations Contact: Investor Relations at Lantern Pharmair@ Sign in to access your portfolio
